[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: High Flow Nasal Cannula (HFNC) group: Group 1 will comprise of patients treated with High flow Nasal cannula. HFNC set at 40-60 L/mt ; FiO2- 0.8-1adjusted to maintain SpO2 SpO2 \u00e2?\u00a5 96- 99 %. Duration of therapy- till the patient improves or goes into severe category of COVIDControl Intervention1: standard non-rebreathing mask (NRBM)group: Group 2 will comprise patients treated with standard non-rebreathing mask. NRBM will be used at a flow rate of 12-15 L/mt FiO2- 0.8-1; adjusted to maintain SpO2 \u00e2?\u00a5 96- 99%.Duration of therapy- till the patient improves or goes into severe category of COVID", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: High Flow Nasal Cannula (HFNC) group: Group 1 will comprise of patients treated with High flow Nasal cannula. HFNC set at 40-60 L/mt ; FiO2- 0.8-1adjusted to maintain SpO2 SpO2 \u00e2?\u00a5 96- 99 %. Duration of therapy- till the patient improves or goes into severe category of COVID", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: standard non-rebreathing mask (NRBM)group: Group 2 will comprise patients treated with standard non-rebreathing mask. NRBM will be used at a flow rate of 12-15 L/mt FiO2- 0.8-1; adjusted to maintain SpO2 \u00e2?\u00a5 96- 99%.Duration of therapy- till the patient improves or goes into severe category of COVID", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 575, "treatment_name": "High flow nasal cannula", "treatment_type": "Respiratory support", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "N/A", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: High Flow Nasal Cannula (HFNC) group: Group 1 will comprise of patients treated with High flow Nasal cannula. HFNC set at 40-60 L/mt ; FiO2- 0.8-1adjusted to maintain SpO2 SpO2 \u00e2?\u00a5 96- 99 %. Duration of therapy- till the patient improves or goes into severe category of COVIDControl Intervention1: standard non-rebreathing mask (NRBM)group: Group 2 will comprise patients treated with standard non-rebreathing mask. NRBM will be used at a flow rate of 12-15 L/mt FiO2- 0.8-1; adjusted to maintain SpO2 \u00e2?\u00a5 96- 99%.Duration of therapy- till the patient improves or goes into severe category of COVID", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: High Flow Nasal Cannula (HFNC) group: Group 1 will comprise of patients treated with High flow Nasal cannula. HFNC set at 40-60 L/mt ; FiO2- 0.8-1adjusted to maintain SpO2 SpO2 \u00e2?\u00a5 96- 99 %. Duration of therapy- till the patient improves or goes into severe category of COVID", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: standard non-rebreathing mask (NRBM)group: Group 2 will comprise patients treated with standard non-rebreathing mask. NRBM will be used at a flow rate of 12-15 L/mt FiO2- 0.8-1; adjusted to maintain SpO2 \u00e2?\u00a5 96- 99%.Duration of therapy- till the patient improves or goes into severe category of COVID", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]